Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT: RP2 for High-Risk Oral Precancerous Disease
NCT06623110Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of sturlimogene erparepvec in oral potentially malignant disorder (OPMD). Started Jan 2025; status: recruiting.
02
Drugs
sturlimogene erparepvec
03
Conditions
oral potentially malignant disorder (OPMD)
Beyond the preview
Go deeper on NCT06623110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623110.